Tradestie Institutional Equity Comparison Engine

ARTV vs MBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ARTV Overall Edge

ARTV Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Artiva Biotherapeutics, Inc. Common Stock (ARTV) driven by superior Momentum & Technical, Options & Structure while MBIO counters with relative strength in Growth & Margin. Fundamentally, ARTV trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ARTV N/M vs MBIO N/M Fwd P/E
Growth & Margin Winner MBIO
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner ARTV
1Y +19.4% vs -68.4% ยท 52W Pos 8% vs 3%
Options & Structure Winner ARTV
BREAKDOWN (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
ARTV NASDAQ
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.88
-2.02% 1D
Market Cap $198.2M
1M Return -34.13%
1Y Return +19.38%
Forward P/E N/M
Unified AI Score
48.5 / 100 HOLD
Tech 50.0 Fund 60.0 Flow 64.0 Mom 59.0
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
1M Return +3.22%
1Y Return -68.44%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ARTV +19.38% MBIO -68.44% Spread: +87.82 pp (ARTV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ARTV TTM Op. Margin: 0.0% MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARTV vs MBIO. Trailing 12-month operating profitability (ARTV 0.0% vs MBIO 0.0%) and valuation multiples (ARTV N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ARTV (3) vs MBIO (3)
Institutional Metric ARTV MBIO Criterion Row Winner
Market Capitalization Scale $198.2M $3.2M Larger Scale ARTV
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +0.0% Higher Growth MBIO
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -43.6% -43.1% Higher ROE MBIO
52-Week Range Position Momentum 8% ($3โ€“$15) 3% ($0โ€“$1) Stronger Trend ARTV
Beta / 30D Volatility Risk Regime 1.73ฮฒ ยท 114% Vol 0.69ฮฒ ยท 85% Vol Lower Realized Risk MBIO
Unified Institutional Score Composite Signal 48.5 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite ARTV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ARTV vs MBIO Buy Guide
ARTV BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ARTV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ARTV nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.